Premium
Stem cell mobilization by G‐CSF in solid and hematological malignancies: Single daily dose is better than split dose in obese patients
Author(s) -
Çetin Türker,
Arpaci Fikret,
Özet Ahmet,
Öztürk Bekir,
Kömürcü Şeref,
İhsan Uzar Ali,
Yilmaz İlker,
Beyzadeoĝlu Murat,
Oysul Kaan,
Ataergin Selmin,
Kuzhan Okan,
Pekel Aysel
Publication year - 2003
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.10068
Subject(s) - medicine , hematological disorders , mobilization , oncology , stem cell , immunology , genetics , biology , archaeology , history
In the past, variable results were reported for single daily and two divided daily doses of granulocyte colony‐stimulating factor (G‐CSF) in stem cell collection where no study exists investigating the effect of body mass index (BMI) on mobilization. The numbers of CD34 + cells collected were compared in 86 patients with solid or hematological malignancies receiving either single daily (14 μg/kg/day) G‐CSF (filgrastim) as group I (n=36) or two divided doses of G‐CSF daily (2 × 7 μg/kg/day) as group II (n = 50). Both groups were divided into subgroups according to their BMI as group a (BMI ≤25 kg/m 2 ) and group b (BMI >25 kg/m 2 ). Two groups were similar in terms of BMI, gender, and disease characteristics. All patients have received G‐CSF as a single or two divided doses subcutaneously and aphereses have been done on the 5th day. No significant difference in numbers of CD34 + cells between groups Ia and Ib, groups IIa and IIb, and groups Ia and IIa was found. On the other hand, the mean ratio and the number of CD34 + cells in group Ib were significantly higher than those of group IIb (0.58 ± 0.06% vs. 0.37 ± 0.26%, P = 0.01 and 3.67 ± 0.65 × 10 4 /kg/ml vs. 1.92 ± 0.37 × 10 4 /kg/ml, P = 0.02). In conclusion, in patients with BMI >25 kg/m 2 , once daily G‐CSF compared to split dose administration induces a greater number of CD34 + stem cell mobilization, which suggests the presence of a different pharmacokinetics in obese patients. J. Clin. Apheresis 18:120–124, 2003. © 2003 Wiley‐Liss, Inc.